Author

E. C. Vatansever

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 6 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:drug response / drug discovery· 6 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Organism:virus· 2

Frequent Co-Authors

S. Xu· 8 shared W. R. Liu· 8 shared Y. Ma· 7 shared X. R. Ma· 6 shared Y. R. Alugubelli· 6 shared C.-C. Cho· 5 shared Z. Z. Geng· 5 shared G. Yu· 4 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersBiochemistry

S. Xu

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease

K. Khatua, Y. R. Alugubelli, K. Yang, V. Reddy, L. Blankenship, D. Coleman, S. Atla, S. Chaki, Z. Geng, X. Ma, J. Xiao, P.-H. Chen, C.-C. Cho, E. C. Vatansever, Y. Ma, , W. R. Liu

This study develops an azapeptide platform with covalent warheads to identify potent SARS-CoV-2 MPro inhibitors, including MPI89 with a 10 nM EC50 and high selectivity.

bioRxiv · Apr 11, 2023 · PreprintBiochemistry

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

Z. Z. Geng, S. Atla, N. Shaabani, V. R. Vulupara, K. S. Yang, Y. R. Alugubelli, K. Khatua, P.-H. C. Chen, J. Xiao, L. R. Blankenship, X. R. Ma, E. C. Vatansever, C.-C. Cho, Y. Ma, R. Allen, , W. R. Liu

This study systematically evaluates dipeptidyl inhibitors of SARS-CoV-2 main protease, identifying compounds with high antiviral potency and low cytotoxicity.

bioRxiv · Jan 17, 2023Biochemistry

The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors

Y. R. Alugubelli, Z. Z. Geng, K. Yang, N. Shaabani, K. Khatua, X. R. Ma, E. C. Vatansever, C.-C. Cho, Y. Ma, L. Blankenship, G. Yu, B. Sankaran, P. Li, R. Allen, H. Ji, , W. R. Liu

This paper identifies that a P4 N-terminal carbamate in boceprevir-based inhibitors is crucial for high antiviral potency against SARS-CoV-2.

bioRxiv · Dec 18, 2021 · PreprintBiochemistry

The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors

Y. Ma, K. Yang, Z. Z. Geng, Y. R. Alugubellia, N. Shaabani, E. C. Vatansever, X. R. Ma, C.-C. Cho, K. Khatua, L. Blankenship, G. Yu, B. Sankaran, P. Li, R. Allen, H. Ji, , W. R. Liu

This study identifies O-tert-butyl-threonine at the P3 site as critical for enhancing cellular and antiviral potency of MPro inhibitors.

bioRxiv · Dec 18, 2021 · PreprintBiochemistry

MPI8 is Potent Against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L

X. R. Ma, Y. R. Alugubelli, Y. Ma, E. C. Vatansever, D. A. Scott, Y. Qiao, G. Yu, S. Xu, W. R. Liu

The paper evaluates MPro inhibitors for SARS-CoV-2, finding MPI8 selectively inhibits both MPro and host cathepsin L, enhancing antiviral efficacy with reduced toxicity.

bioRxiv · Jun 10, 2021Pharmacology & Toxicology

Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics

W. Cao, C.-C. D. Cho, Z. Z. Geng, X. R. Ma, R. Allen, N. Shaabani, E. C. Vatansever, Y. R. Alugubelli, Y. Ma, W. H. Ellenburg, K. S. Yang, Y. Qiao, H. Ji, S. Xu, W. R. Liu

This paper evaluates the cellular potency of SARS-CoV-2 MPro inhibitors using a fluorescent flow cytometry assay, revealing that most inhibitors have weak cellular activity despite strong antiviral effects.

bioRxiv · Jun 8, 2021 · PreprintBiochemistry

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

W. R. Liu, K. S. Yang, X. R. Ma, Y. Ma, Y. R. Alugubelli, D. A. Scott, E. C. Vatansever, A. K. Drelich, Z. Z. Geng, L. R. Blankenship, B. Sankaran, H. E. Ward, Y. J. Sheng, J. C. Hsu, K. K. Kratch, , H. S. Hayatshahi

This study designs and synthesizes potent SARS-CoV-2 main protease inhibitors, with some showing IC50 values below 100 nM and high virus inhibition potency in cell assays.

bioRxiv · Jul 28, 2020 · PreprintBiochemistry

Bepridil is Potent Against SARS-CoV-2 In Vitro

E. C. Vatansever, K. S. Yang, K. C. Kratch, A. Drelich, C.-C. Cho, D. M. Mellott, S. Xu, C.-T. K. Tseng, W. R. Liu

This study identifies bepridil as a potent inhibitor of SARS-CoV-2 MPro and virus entry, showing efficacy in vitro at low concentrations.

bioRxiv · May 23, 2020Pharmacology & Toxicology